Mystery Behind the Departure of the Head of Xingyue Health (星悦康旅)

Exit and succession

Xingyue Health (星悦康旅; 03662.HK), formerly Aoyuan Healthy (奥园健康), announced on March 16 that chairman and group CEO Wang Jiren (王吉人) has resigned for “personal family matters,” stepping down from all executive roles. The move — quiet and abrupt after nearly two years at the helm — coincides with a March 13 profit warning that forecast 2025 net profit attributable to owners would be halved to HK$50–55 million. Replacements were named immediately: veteran finance executive Liang Jinrong (梁金蓉) as board chair and 33‑year‑old Tao Yu (陶宇) as executive director and authorised representative.

Past, reputation and reappointment

Wang, a PhD graduate from The Hong Kong Polytechnic University with earlier degrees from Jinan University and Nankai University, took charge on May 17, 2024 after a state‑linked investor, Nanyue Xingqiao Fund (南粤星桥基金), became the largest shareholder as part of the company’s “national capitalisation” transition. It has been reported that he was brought in to steady a business still recovering from its ties to the former Aoyuan property group and to rebuild market confidence. His departure leaves a leadership team that remains dominated by executives from the Aoyuan era.

Regulatory shadow and governance questions

The most controversial appointment is Tao Yu, who was publicly censured by the Hong Kong Exchanges and Clearing (HKEX) in January over a 2019–2022 episode in which the group routed about RMB 3.3 billion through 147 transactions to benefit the then‑controlling Aoyuan group; HKEX found failures of oversight and ordered Tao to complete 26 hours of compliance training. The board defended the hire, saying the matter did not involve dishonesty, that Tao has completed the required training, and that his experience will aid the group — a line that will test investor patience. Why reinstate a director with a regulatory “historical imprint”? Reportedly, the company values institutional memory and crisis‑management experience; critics argue it risks signalling tolerance of past governance lapses.

Financial picture and what’s next

The profit warning cited five drags — lower FX gains, reduced bank interest income, goodwill impairment, fair‑value losses on a medical‑aesthetics investment and higher project spending — yet the company says core operating profit (excluding non‑recurring items) is roughly flat year‑on‑year at about RMB 97–107 million. So the headline drop is partly accounting‑driven. Still, in an environment of heightened regulatory scrutiny in Hong Kong and with state capital now prominent in ownership, investors will watch whether the new leadership can translate technical steadiness into renewed market trust. Will continuity outweigh controversy? That is the question facing Xingyue’s post‑Aoyuan reset.